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Abstract
Background: IL-10 is an immunoregulatory cytokine that increases during malignant diseases. The purpose of this
study was to: i) determine the mRNA amounts of IL-10, IL-10Rα, and IL-10Rβ in cutaneous and uveal melanoma cells
and specimens; ii) evaluate their post-transcriptional regulation by miRNAs; iii) ascertain whether miRNA
dysregulation may affect IL-10-induced proliferation.
Methods: Genome-wide miRNA expression profiling was performed using a human microarray platform. The
reference gene mRNA was measured through qPCR. miRNAs/mRNAs interactions were predicted by TargetScan,
microRNA, and PITA. Transfections of specific miRNA mimics/inhibitors were carried out. Cell proliferation was
assessed by MTT assay in the presence of IL-10 after transfection with miRNA mimics/inhibitors.
Results: There were no differences in IL-10 mRNA levels between any of the 3 melanoma cell lines tested and
normal melanocytes. However, lower IL-10Rα expression was found in G361 and OCM-1 cells, and higher levels of IL-
10Rβ were observed in G361 cells compared with normal melanocytes. GR-M cells did not exhibit any modifications
in IL-10Rα and IL-10Rβ expression. miR-15a, miR-185, miR-211, and miR-30d were upregulated in G361 and OCM-1
cells, remaining at similar levels in GR-M cells. miR-409-3p and miR-605were down-regulated exclusively in G361
cells. Prediction tools revealed that miR-15a, miR-185, and miR-211 targeted IL-10Rα whereas none of the miRNAs
exclusively downregulated in G361 cells targeted IL-10Rβ. Luciferase reporter and western blot assays showed that
IL-10Rα expression is directly regulated by miR-15a, miR-185, and miR-211, either alone or in combination. An
inverse expression pattern between IL-10Rα, on one side, and miR-15a, miR-185, and miR-211 on the other one was
also shown in melanoma samples. Ectopic expression of individual miR-15a, miR-185, and miR-211, and even more
their co-expression, caused a marked decrease in the proliferation rate of all the cell lines. Likewise, inhibition of any
specific miRNA promoted cell growth, an effect that further increased when inhibition concerned all three miRNA.
Moreover, specific knockdown of IL-10Rα prevented the proliferative effect of miRNA inhibitors.
Conclusions: Our results support a key role of IL-10Rα in the development and progression of melanoma and
suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment.
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Background
IL-10 is generally believed to repress the inflammatory re-
sponse [1] and immune reactions against a variety of tu-
mors [2, 3]. This cytokine is secreted by immune and
non-immune cells [4] and its production was found to in-
crease during malignant diseases, including melanoma [5].
The ability of IL-10 to affect melanoma growth under a
variety of conditions renders this cytokine an interesting
topic of research in this field, although the mechanisms
involved are complex and incompletely understood [6–8].
Some studies suggested that high local levels of this
cytokine may favor melanoma growth by suppressing
the activities of tumor-infiltrating cells involved in anti-
tumor immunity. For example, it was shown that IL-10
can decrease proinflammatory cytokine expression [9]
or anti-tumor T cell responses [7, 9]. These data sug-
gested that the production of IL-10 by melanoma cells
and its release in the surrounding microenvironment
might produce a paralysis of the anti-melanoma im-
mune response [5].
In contrast, other studies indicate that IL-10 may aug-
ment the effects of anti-melanoma vaccination [10] or
inhibit melanoma metastasis through activation of NK
cells [6]. Moreover, it was reported that IL-10 repressed
tumor growth and the metastatic potential of melanoma
cells by inhibiting the expression of angiogenic factors
and, thereby, vascularization [8]. Irrespectively of the ef-
fects of IL-10 on the immune response, the direct effects
of this cytokine on melanoma cell themselves have been
only incompletely addressed, although one study sug-
gested that IL-10 might function as an autocrine growth
factor [7].
Expression of the IL-10Ron the cell surface is abso-
lutely required for the responsiveness to this cytokine,
but its role is in the context of melanoma development
is ill-understood. IL-10R is composed of two different
chains (IL-10Rα and IL-10Rβ). The alpha chain binds
directly to IL-10 and the beta chain is subsequently re-
cruited into the IL-10/IL-10Rα complex. Although it is
generally believed that signal transduction pathways are
triggered only after binding of the beta chain, it cannot
be ruled out that this occurs also during initial binding
of IL-10 to IL-10Rα [4].
Emerging evidence suggests a role for epigenetic
modulation in melanomagenesis. In particular, miRNAs
have been recognized as important mediators of bio-
logical processes linked to melanoma, including growth,
cell cycle, invasiveness, migration, and immune evasion
[11]. Given that very few data are available about the
post-transcriptional regulation of the IL-10 system and
its role in melanoma cell behavior, we aimed at investi-
gating the involvement of miRNAs in the expression




G361 cutaneous melanoma cells (ECACC, European
Collection of Cell Cultures, Salisbury, UK) were grown
in McCoy’s 5a medium modified with 10 % FBS,
2 mM L-glutamine, and 1 % penicillin/streptomycin.
The cutaneous melanoma cell line GR-M (ECACC,
European Collection of Cell Cultures, Salisbury, UK)
and the uveal melanoma cell line OCM-1 (provided by J.
Mellon, Department of Ophthalmology, UT Southwest-
ern Medical Center, Dallas, TX) were cultured in RPMI
1640 medium supplemented with 2 mM L-glutamine,
1 % penicillin/streptomycin, and 10 % FBS.
Tumor specimens
To exclude that our observations were restricted to cell
lines maintained in long-term culture, we also examined
primary tumors. Formalin-fixed paraffin-embedded
(FFPE) tissue sections of 52 cutaneous melanomas (31
females and 21 males, age ranging from 45 to 65 years),
41 uveal melanomas (15 females and 26 males, age ran-
ging from 52 to 68 years), and 35 normal skin speci-
mens, taken from patients of the University Hospital of
Messina, were examined. The investigation adhered to
the Declaration of Helsinki and was approved by the
Ethics Committee of the University Hospital of Messina.
An informed verbal consent was given by patients.
Total RNA extraction, reverse transcription and qPCR
Total RNA was extracted by TRIzol Reagent (Invitro-
gen). RNA samples were quantified with a Nanodrop
1000 spectrophotometer and their quality was evaluated
using Agilent RNA 6000 Nano Assay. RNA samples
were converted into cDNA using IMProm-II™ reverse
transcriptase kit (Promega). Quantitative Real-Time PCR
was performed by ABI Prism 7500 Real-Time PCR Sys-
tem (Applied Biosystems, Milan, Italy) with SYBR Green
Mastermix (Applied Biosystems, UK). Primers were
previously reported [12, 13]. The mRNA levels of IL-10,
IL-10Rα, and IL-10Rβ were normalized to endogenous β-
actin (Applied Biosystems).
miRNA microarray
miRNA microarray experiments were performed using a
human miRNA microarray platform (Agilent Sanger
miRBase, release 10.1) with 723 human and 76 human
viral miRNAs represented. Agilent Feature Extraction
Software was used for background subtraction. LOWESS
and Quantile normalizations were performed.
Oligonucleotide transfection
MiR-15a, miR-185, and miR-211 mimics/inhibitors
(Qiagen, Milan, Italy) were transfected either alone or
in combination into melanoma cells using HiPerFect
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according to the manufacturer’s protocols (Qiagen).
Cells were transfected twice with 100 pmol of oligo-
nucleotide per well (0.5 × 106 cells) at 24 h intervals.
Transfected cells were assayed 48 h after the second
transfection.
Western blot analysis
Total cell extracts (50 μg) were resolved by SDS-PAGE
and blotted onto nitrocellulose membranes with specific
antibodies against IL-10 (sc-8438, Santa Cruz Biotech-
nology), IL-10Rα (sc-984, Santa Cruz Biotechnology),
and IL-10Rβ (sc-514822, Santa Cruz Biotechnology).
Plasmids constructs and transient transfections
The 3′-UTR of IL-10Rα and a mutation sequence were
amplified by PCR using the primers with a Bgl II restric-
tion site on each 5′ or 3′ strand. The PCR products
were inserted into the Bgl II sites of the pGL3-control
vector (Promega, Madison, WI, USA) and identified by
DNA sequencing. The wild-type plasmids were created
containing the 3′-UTR of IL-10Rα with complementary
sequence of miR-15α ( IL-10Rα 3′-UTR wild 1), miR-
185 (IL-10Rα 3′-UTR wild 2), miR-211 ( IL-10Rα 3′-
UTR wild 3) or covering all the three miRNA side sites
(IL-10Rα 3′-UTR wild-full-length). Four mutant plas-
mids were generated with the mutation sequence with-
out complementary sequence of miR-15a (pGL3- IGF-1
3′-UTR mut 1), miR-185 (pGL3- IGF-1 3′-UTR mut 2),
and miR-211 (pGL3- IGF-1 3′-UTR mut 3) or all of
them (IL-10Rα 3′-UTR mut-full-length). For the lucifer-
ase reporter assay, cells were seeded on 24-well plates
and co-transfected using Lipofectamine 2000 (Invitro-
gen) with 100 ng per well of the resulting luciferase
UTR-report vector, 2 ng per well of pRLCMV vector (in-
ternal control, Promega), and 20 ng per well of miR-15a,
miR-185, and miR-211 mimics or inhibitors following
the manufacturer’s instructions (Qiagen, Milan, Italy).
After 24 h, the cells were lysed, and the relative lucifer-
ase activity was assessed with the Dual-Luciferase Assay
Reporter System (Promega). For transient knockdown of
IL-10Rα, cells were transfected with specific small inter-
fering RNA (siRNA) targeting IL-10Rα or non-targeting
control siRNA (Santa Cruz Biotechnology, Milan, Italy)
24 h after plating using Lipofectamine 2000 (Invitrogen)
with the siRNA at a final concentration of 100 nM.
Cell proliferation assay
Cells were treated with recombinant human IL-10 (R
& D Systems) at various doses (50, 100, or 500 U/ml)
and for different times (at 6-hr intervals during a 72-hr
culture period) accordingly to previously reported con-
ditions [7]. Proliferation was measured using the MTT
Assay Kit (Cayman Chemical Company, Michigan,
USA).
Densitometry and statistical analysis
The one-way analysis of variance (ANOVA) test, followed
by a pair-wise multiple comparison test (Bonferroni t test),
was performed to identify the differences among the
groups. The relative intensities of protein bands were ana-
lyzed by Image J software (Bethesda, MD, USA). Statistical
significance was assigned when the p value was <0.05.
Results
Expression levels of IL-10, IL-10Rα, and IL-10Rβ in
cutaneous and uveal melanoma cells
The mRNA content of IL-10 and its receptor subunits
(IL-10Rα and IL-10Rβ) was analyzed by quantitative PCR
(qPCR) in two cutaneous (G361 and GR-M) and one
uveal (OCM-1) melanoma cell lines and compared to
that of NHEM. As shown in Fig. 1, levels of IL-10
mRNA expression did not significantly differ from that
of NHEM in any of the cell lines examined. Lower
amounts of IL-10Rα expression were found in G361 and
OCM-1 cells, and higher levels of IL-10Rβ were ob-
served in G361 cells. GR-M did not exhibit any modifi-
cations in IL-10Rα or IL-10Rβ expression.
Prediction of miRNAs targeting IL-10Rα and IL-10Rβ
To test for possible post-transcriptional modulation of IL-
10Rα and IL-10Rβ expression by miRNAs, genome-wide
miRNA expression profiling was carried out. Figure 2
(sections B and C) shows that, as compared to NHEM,
only 4 miRNAs (miR-15a, miR-185, miR-211, and miR-
30d) were upregulated in G361 and OCM-1 cells, while
remaining at similar levels in GR-M cells. Two miRNAs
(miR-513a-5p and miR-551b) were down-regulated exclu-
sively in G361 cells. The expression levels of these miR-
NAs were confirmed by qPCR (data not shown).
To predict miRNAs/mRNAs interactions, TargetScan
(http://www.targetscan.org/), microRNA (www.micror-
na.org/) and PITA (http://genie.weizmann.ac.il/pubs/
mir07/mir07_data.html) were used. Three out of the
four miRNAs upregulated in G361 and OCM-1 and un-
changed in GR-M were predicted to have seed regions
able to bind to the 3′UTR of IL-10Rα (miR-15a was re-
ported in all the miRNA target prediction systems, miR-
185 in microRNA and PITA; miR-211 in microRNA and
PITA). None of the miRNAs exclusively downregulated
in G361 cells had IL-10Rβ as a putative target transcript.
IL-10Rα is a target of miR15a, miR185, and miR211
To validate the direct interaction of miR15a, miR185, and
miR211 with IL-10Rα mRNA (Fig. 3a), we constructed a
luciferase reporter system containing a binding site (IL-
10Rα-3′-UTR-wt) or a mutated site (IL-10Rα-3′-UTR-
mut). The vectors were co-transfected into G361, GR-M,
and OCM-1 cells with miR15a, miR185, and miR211
mimics or inhibitors. The luciferase activity of IL-10Rα-
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3′-UTR-wt in cells transfected with miR-15a, or miR-185,
or miR-211 mimics was significantly decreased (p < 0.001),
compared to negative controls. When the three mimics
were co-transfected, luciferase activity was almost abol-
ished. However, none of them, either alone or in
combination, affected the transcription of the pGL3-IL-
10Rα-mut vector (Fig. 3b). When blocking the expression
of the three miRNAs with specific inhibitors, luciferase in-
tensity markedly increased in cells transfected with the IL-
10Rα-3′-UTR-wt vector (p < 0.001). This increase was
higher when cells were co-transfected with all the three
inhibitors. No change in cells transfected with pGL3-IL-
10Rα-mut (Fig. 3c) was observed. These results suggest
that the 3′-UTR of IL-10Rα mRNA might be the target of
miR15a, miR185, and miR211. Next, we further investi-
gated the regulation of IL-10Rα protein expression by
miR-15a, miR-185, and miR-211. Western blot showed
that the IL- 10Rα expression significantly decreased in
cells transfected with individual mimics and was almost
abolished by their combination. IL-10 and IL-10Rβ were
not affected by any of the miRNA mimics either alone or
in combination (Fig. 3d).
The IL-10/IL-10R system and miR-15a, miR-185, miR-211
expression in cutaneous and uveal melanoma samples
Next, we proceeded to explore the expression of the
members of IL-10/IL-10R system, miR-15a, miR-185,
and miR-211 in cutaneous and uveal melanoma samples
as compared to normal skin. Figure 4 shows significant
higher levels of IL-10Rα (section A) accompanied by a
correspondent decrease in miR-15a, miR-185, and miR-
211 (section B) in tumor specimens. IL-10 and IL-10Rβ
did not show significant modification in their expression
levels (section A).
Effects of miR-15a, miR-185, and miR-211 on IL-10-
induced melanoma cell proliferation
As the melanoma environment is characterized by high
levels of IL-10 [14], we analyzed the effects of miR-15a,
miR-185, and miR-211 on the growth of melanoma cells
exposed to this cytokine. Firstly, cells were cultured in
presence of various doses of IL-10 (50, 100, or 500 U/ml),
and the proliferation was determined at 6-hr intervals dur-
ing a 72-hr culture period. As seen in Fig. 5a, relative to
cells with medium alone, the proliferation of GR-M cells
dramatically increased during the 12–48 h interval fol-
lowing treatment with IL-10 at concentrations ranging
from100 through 500 U/ml. G361 and OCM-1 cells
showed a slight, non-significant increase in cell growth
after exposure to IL-10. These data show that IL-10 was
able to induce optimal proliferative effects in GR-M cells
already at a concentration of 100 U/ml in agreement with
previous studies using T cells [15] and that this increase
was also observed at 500 U/ml. Therefore, treatment
with100 U/ml of IL-10 for 36-hr was used for cell prolifer-
ation assays in the presence of miR-15a, miR-185, and
miR-211 mimics or inhibitors. Proliferation was reduced
after transfection of all the cell lines with individual
miRNA mimics and almost abolished following co-
Fig. 1 Expression levels of IL-10, IL-10Rα, and IL-10Rβ in cutaneous
and uveal melanoma cell lines. Total RNA was extracted from cutaneous
(G361 and GR-M) and uveal (OCM-1) melanoma cells, reverse-
transcribed, and analyzed by qPCR. mRNA levels of IL-10, IL-10Rα, and
IL-10Rβ were normalized by using the housekeeping gene β-actin as the
inner control. Data are depicted as the mean ± SD of three independent
experiments. Significant ***p< 0.001, as compared to NHEM cells
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transfection with the combined mimics (Fig. 5b). Knock-
down of miR-15a, or miR-185, or miR-211 markedly pro-
moted the proliferation in all the cell lines and the
combined inhibitors further increased growth. The prolif-
erative effects of miRNA inhibitors, either alone or in
combination, were abolished when IL-10Rα was silenced
by the specific siRNA (Fig. 5c).
Discussion
IL-10 has been extensively studied for its ability to affect
immune responses against a wide variety of cancers,
and, to a lesser extent, also against the melanoma [4].
Regarding this tumor, conflicting findings are reported,
some of which showing that IL-10 significantly contrib-
utes to melanoma development [7, 9], and some others
indicating that this cytokine strengthens the effects of
anti-melanoma vaccines and NK cells [6, 10]. Moreover,
what are the direct effects of IL-10 on melanoma cells
and whether the latter differ from normal melanocytes
in their responsiveness to the cytokine is presently un-
clear. Here we did not observe any significant changes in
IL-10 expression in the melanoma cell lines studied rela-
tive to normal melanocytes (Fig. 1). However, literature
data are contradictory in this regard, as some papers re-
port that IL-10 is an autocrine melanoma growth factor
[7, 16], others obtained uneven results in their melan-
oma cell systems [5], and still others found that IL-10, as
well as its receptor, are expressed at lower levels in mel-
anoma samples than in healthy skin [14]. In this context,
a more prominent role seemed to be played by IL-10Rα
expression than by IL-10 production, according to our
data (Fig. 1). Indeed, the uveal and cutaneous melanoma
Fig. 2 miRNA expression profiles in cutaneous and uveal melanoma. a Venn diagram illustrating the common and specific miRNAs in the indicated
cells. b Heat map comparing the average fold-changes in microRNAs with significantly higher (red) or lower (green) expression in melanoma cells in
comparison to normal human epidermal melanocytes (NHEM) (FDR ≤0.001). c Heat map relative to the 4 common miRNAs with up-regulated
expression pattern in OCM-1 and G361 cells and the 2 common miRNAs down-regulated exclusively in OCM-1. FDR, false discovery rate
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cell lines OCM-1 and G361, which displayed downregu-
lation of IL-10Rα (with G361 also exhibiting higher IL-
10Rβ expression), did not proliferate after IL-10 treat-
ment, as opposed to GR-M cells with moderate IL-10Rα
expression (Fig. 5). The observation that the two cutane-
ous melanoma cell lines exhibit a different expression
profile and that the cutaneous melanoma line G361 is
similar to the uveal melanoma cell line OCM-1 with re-
spect to IL-10Rα and miRNA expression and responses
to IL-10 is not surprising. Indeed, G361 showed a differ-
ent behavior from GR-M in endogenous retrovirus K
protein Rec expression upon exposure to UV [17] and
from several other cutaneous melanoma cell lines in the
expression of ATP-binding cassette (ABC) B5 mRNA
[18]. On the other hand, G361 exhibited an expression
pattern of DcR1 and DcR2 identical to that of uveal
melanoma cell lines as a result of promoter hypermethy-
lation and a likewise identical responsiveness to the
demethylating agent 5-aza-dC [19]. IL-10R is expressed
on a variety of cells, in particular immune cells, in-
cluding most hematopoietic cells such as monocytes,
macrophages, and T- and B-lymphocytes [4], but is also
expressed on non-hematopoietic cells, such as epidermal
cells or keratinocytes [5]. Only two studies evaluated the
expression of IL-10R on melanoma cells [7, 14]. In an
early study, a comparison was not carried out with nor-
mal melanocytes and no distinction was made between
the two IL-10R chains [7]. A second, more recent study,
after comparing neoplastic melanocytes with normal
skin, reported a great variability in IL-10R expression,
with lower levels of in melanoma, but, again, without a
distinction between α and β chains [14]. This is a
Fig. 3 IL-10Rα is the direct target of miR-15a, miR-185, and miR-211 a Schematic representation of the predicted interaction of miR-15a,
miR-185, and miR-211 with IL-10Rα 3′UTR site. b Luciferase reporter assay was performed to detect the effect of individual or combined miRNA
mimics on the luciferase intensity controlled by 3′UTR of IL-10Rα. Data are depicted as the mean ± SD of three independent experiments.
Significant ***p < 0.001 and ****p < 0.0001, as compared to cells transfected with mimic control. c Luciferase reporter assay was performed to
detect the effect of individual or combined miRNA inhibitors on the luciferase intensity controlled by 3′UTR of IL-10Rα. Data are depicted as
the mean ± SD of three independent experiments. Significant ***p < 0.001 and ****p < 0.0001, as compared to cells transfected with inhibitor
control. d Cells were transfected with individual or combined miRNA mimics and subjected to western blot for IL-10, IL-10Rα, and IL-10Rβ
protein expression. β-actin was used as an internal control for normalization. Blots are representative of three independent experiments.
The relative densities were calculated by dividing the density of IL-10Rα bands by the density of β-actin band at the same point. Significant
**p < 0.01 and *** p < 0.001, as compared to cells transfected with mimic control
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critical gap in the understanding of the role of the IL-
10/IL-10R system in melanoma, since α and β chains
are encoded by distinct genes and display different role
in triggering the signaling events [4]. In this regard,
here we showed that the expression of IL-10Rα is cru-
cial for the melanoma cell responsiveness to IL-10.
Melanocytes play a central role in skin innate immune
system and inflammation [20] to the point that they have
been defined “a sensitive barometer of inflammatory
conditions of the skin” [21]. The recently evidenced role
of miRNA dysregulation in melanoma [11, 22],
prompted us to investigate whether differential expres-
sion of the two chains of IL-10R occurring in the three
different melanoma models was in association with spe-
cific miRNA profiles. We found that as many as three
out of four miRNAs (namely miR-15a, miR-185, and
miR-211) were increased in cells with low expression of
IL-10Rα, and that these regulatory molecules targeted
the IL-10Rα gene (Fig. 2). This conclusion stemmed
from a series of experiments based on miRNA target
prediction tools, miRNA target reporter assay, and west-
ern blot (Fig. 3). The amounts of IL-10 and IL-10Rβ pro-
teins were not affected by the three miRNAs. The
expression profile of IL-10/IL-10R, miR-15a, miR-185,
and miR-211 observed in cutaneous and uveal melanoma
tissues exhibited the same trend observed in melanoma
cell lines (Fig. 4). Interestingly, miR-15a, miR-185, and
miR-211 are thought to function as tumor suppressors in
melanocytes, as they repress many genes implicated in the
melanomagenesis. For example, downregulation of miR-
15a, which is observed in several cancers including melan-
oma, led to an overexpression of several oncogens, such
as Bcl-2, Cyclin D1, and Mcl-1 [23]. In addition, miR-185
exhibits strong anti-proliferative effects on melanoma ei-
ther in-vitro or in vivo [24] and miR-211 inhibits the ag-
gressive and invasive phenotype of melanoma cells [11].
However, to our knowledge, the regulation of IL-10Rα ex-
pression by these three miRNAs and the possible signifi-
cance of IL-10Rα downregulation in melanoma cell
proliferation have not yet been addressed. Here we
Fig. 4 IL-10/IL-10R system and miR-15a, miR-185, miR-211 expression in cutaneous and uveal melanoma samples. Total RNA was extracted from
35 normal skin specimens, 52 cutaneous melanomas, and 41 uveal melanomas, reverse-transcribed, and analyzed by qPCR to determine the relative
amounts of IL-10, IL-10Rα, IL-10Rβ mRNA (a) and miR-15a, miR-185, miR-211 (b). Data are representative of three independent experiments. Means of
the measurements are shown with black lines
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showed that miR-15a, miR-185, and miR-211 mimics
inhibited and miRNA inhibitors increased the prolifera-
tion of IL-10-treated melanoma cells through IL-10 signal-
ing, since the silencing of IL-10Rα cancelled the effects of
miRNA inhibitors on the proliferation (Fig. 5). Another
interesting finding from these experiments is that the
three miRNAs considered exerted synergistic effects
both in modulating the expression of IL-10Rα or in
regulating the proliferation of melanoma cells. These
data suggest the potential usefulness of a combined
therapeutic strategy targeted to the expression of miR-
15a, miR-185, and miR-211 in melanoma cells.
Data presented here acquire perhaps further relevance
in light of a recent paper showing that the expression of
IL-10 and IL-10R, despite the great variability, is lower
in melanomas compared to normal skin [14]. In this
context, our findings give emphasis to whether or not
melanoma cells express IL-10Rα, as the expressing cells
proliferated in the presence of IL-10 – which may be
produced by melanoma environment – while the non-
expressing melanoma cells were unresponsive to the
cytokine. Therefore, our data add to our knowledge
about the significance of IL-10Rα post-transcriptional
regulation in the characteristics of malignancy of melan-
oma, independently from the questioned immunostimu-
lant or immunosuppressive role of IL-10.
Conclusions
Taken together, findings reported in the present study
suggest that the IL-10Rα expression in melanoma cells is
post-transcriptionally regulated by miR-15a, miR-185,
and miR-211. The variability in IL-10Rα mRNA amounts
we observed is correlated with the differences in cell
growth in response to IL-10. Thus, it could be argued
Fig. 5 Effects of miR-15a, miR-185, and miR-211 on IL-10-induced melanoma cell growth. a Cells were cultured in the presence of various doses of
rIL-10: 0 (as negative control), 50, 100, or 500 U/ml and proliferation was assessed by MTT assay. Absorbance at 570 nm was measured at 6-hr intervals
over a 72-hr culture period. Each experiment was repeated three times, and data represent the mean ± SD of three determinations. Significant
**p < 0.01 and ***p < 0.001, cells treated with 100 U/ml as compared to the negative control at the same time point. Significant °p< 0.05 and °°p < 0.01,
cells treated with 500 U/ml as compared to the negative control at the same time point. b Cells were transfected with individual or combined miR-15a,
miR-185, and miR-211 mimics for 48-hr and then treated with rIL-10 (100 U/ml) for 36-hr. Proliferation was determined as reported in section A. Significant
**p < 0.01 and ***p < 0.001, as compared to untransfected cells. c Cells were transfected with individual or combined miR-15a, miR-185, and
miR-211 inhibitors for 48-hr and, where indicated, co-transfected with siRNA against IL-10Rα or non-targeting control siRNA. Then, cells were
treated with rIL-10 (100 U/ml) for 36-hr. Proliferation was determined as reported in section A. Significant **p < 0.01 and ***p < 0.001, as
compared to untransfected cells
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the IL-10/IL-10 receptor system may become a new epi-
genetic therapeutic target for melanoma treatment.
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